keyword
https://read.qxmd.com/read/38630892/disruption-of-klhl6-fuels-oncogenic-antigen-receptor-signaling-in-b-cell-lymphoma
#1
JOURNAL ARTICLE
Leo Meriranta, Selma Sorri, Kanutte Huse, Xiaonan Liu, Ivana Spasevska, Sadia Zafar, Iftekhar Chowdhury, Olli Dufva, Eerika Sahlberg, Luka Tandaric, Marja-Liisa Karjalainen-Lindsberg, Marko Hyytiainen, Markku Varjosalo, June H Myklebust, Sirpa Leppa
Pathomechanisms that activate oncogenic B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma (DLBCL), are largely unknown. Kelch-like family member 6 (KLHL6) encoding a substrate-adapter for Cullin-3-RING E3 ubiquitin-ligase (CRL) with poorly established targets is recurrently mutated in DLBCL. By applying high-throughput protein interactome screens and functional characterization, we discovered that KLHL6 regulates BCR by targeting its signaling subunits CD79A and CD79B. Loss of physiological KLHL6 expression pattern was frequent among the MCD/C5-like activated B-cell DLBCLs and was associated with higher CD79B levels and dismal outcome...
April 17, 2024: Blood cancer discovery
https://read.qxmd.com/read/38628245/identification-of-mycobacterium-tuberculosis-resistance-to-common-antibiotics-an-overview-of-current-methods-and-techniques
#2
REVIEW
Xue-Song Xiong, Xue-Di Zhang, Jia-Wei Yan, Ting-Ting Huang, Zhan-Zhong Liu, Zheng-Kang Li, Liang Wang, Fen Li
Multidrug-resistant tuberculosis (MDR-TB) is an essential cause of tuberculosis treatment failure and death of tuberculosis patients. The rapid and reliable profiling of Mycobacterium tuberculosis (MTB) drug resistance in the early stage is a critical research area for public health. Then, most traditional approaches for detecting MTB are time-consuming and costly, leading to the inappropriate therapeutic schedule resting on the ambiguous information of MTB drug resistance, increasing patient economic burden, morbidity, and mortality...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38625662/targeting-kras-g12c-in-non-small-cell-lung-cancer-current-standards-and-developments
#3
REVIEW
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, María Zurera Berjaga, Jorge Esteban-Villarrubia, Jon Zugazagoitia Fraile, Luis Paz-Ares
Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene homolog (KRAS). KRAS mutant NSCLC is a heterogenous group of diseases, different from other oncogene-driven tumors in terms of biology and response to therapies. Despite efforts to develop drugs aimed at inhibiting KRAS or its signaling pathways, KRAS had remained undruggable for decades. The discovery of a small pocket in the binding switch II region of KRASG12C has revolutionized the treatment of KRASG12C -mutated NSCLC patients...
April 16, 2024: Drugs
https://read.qxmd.com/read/38624197/polysaccharide-intercellular-adhesin-and-proper-phospholipid-composition-are-important-for-aggregation-in-tetragenococcus-halophilus-sl10
#4
JOURNAL ARTICLE
Airi Yanagihara, Kouta Matsue, Kurumi Kobayashi, Takura Wakinaka, Yoshinobu Mogi, Jun Watanabe
Aggregating strains of Tetragenococcus halophilus tend to be trapped during soy sauce mash-pressing process and are, therefore, critical for clear soy sauce production. However, the precise molecular mechanism involved in T. halophilus aggregation remains elusive. In previous studies, we isolated a number of aggregating strains, including T. halophilus AB4 and AL1, and showed that a cell surface proteinaceous aggregation factor is responsible for their aggregation phenotype. In the present study, we explored the role of polysaccharide intercellular adhesin (PIA) in aggregate formation in T...
April 16, 2024: Applied and Environmental Microbiology
https://read.qxmd.com/read/38621650/perioperative-immunotherapy-for-node-negative-non-small-cell-lung-cancer-current-evidence-and-future-directions
#5
REVIEW
Muhammad H Shahzad, Jonathan D Spicer, Valerie W Rusch, Peter J Kneuertz
Neoadjuvant immunotherapy has gone from an idea to an indication in locally advanced lung cancer. Several phase III trials have demonstrated the superiority of neoadjuvant chemoimmunotherapy compared to chemotherapy in this setting. Although such progress has revolutionized the treatment of locally advanced disease, the unmet needs of stage I and stage II patients without lymph node disease have largely been under-represented in existing trials. Up-front surgery with few patients going on to complete adjuvant therapy remains the norm for most stage I-II patients...
April 13, 2024: Annals of Thoracic Surgery
https://read.qxmd.com/read/38617914/design-synthesis-and-evaluation-of-purine-and-pyrimidine-based-kras-g12d-inhibitors-towards-potential-anticancer-therapy
#6
JOURNAL ARTICLE
So-Youn Park, Venu Venkatarame Gowda Saralamma, Sagar Dattatraya Nale, Chang Joong Kim, Yun Seong Jo, Mohammad Hassan Baig, JungHwan Cho
Oncogenic RAS mutations, commonly observed in human tumors, affect approximately 30% of cancer cases and pose a significant challenge for effective cancer treatment. Current strategies to inhibit the KRAS G12D mutation have shown limited success, emphasizing the urgent need for new therapeutic approaches. In this study, we designed and synthesized several purine and pyrimidine analogs as inhibitors for the KRAS G12D mutation. Our synthesized compounds demonstrated potent anticancer activity against cell lines with the KRAS G12D mutation, effectively impeding their growth...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38617829/myoclonus-and-dystonia-as-recurrent-presenting-features-in-patients-with-the-sca21-associated-tmem240-p-pro170leu-variant
#7
Ugo Sorrentino, Luigi M Romito, Barbara Garavaglia, Mario Fichera, Isabel Colangelo, Holger Prokisch, Juliane Winkelmann, Jan Necpal, Robert Jech, Michael Zech
BACKGROUND: Spinocerebellar ataxia 21 (SCA21) is a rare neurological disorder caused by heterozygous variants in TMEM240 . A growing, yet still limited number of reports suggested that hyperkinetic movements should be considered a defining component of the disease. CASE SERIES: We describe two newly identified families harboring the recurrent pathogenic TMEM240 p.Pro170Leu variant. Both index patients and the mother of the first proband developed movement disorders, manifesting as myoclonic dystonia and action-induced dystonia without co-occurring ataxia in one case, and pancerebellar syndrome complicated by action-induced dystonia in the other...
2024: Tremor and Other Hyperkinetic Movements
https://read.qxmd.com/read/38613395/transcription-factor-olig2-is-a-major-downstream-effector-of-histone-demethylase-phf8-during-oligodendroglial-development
#8
JOURNAL ARTICLE
Marco Kremp, Tim Aberle, Elisabeth Sock, Bettina Bohl, Simone Hillgärtner, Jürgen Winkler, Michael Wegner
The plant homeodomain finger protein Phf8 is a histone demethylase implicated by mutation in mice and humans in neural crest defects and neurodevelopmental disturbances. Considering its widespread expression in cell types of the central nervous system, we set out to determine the role of Phf8 in oligodendroglial cells to clarify whether oligodendroglial defects are a possible contributing factor to Phf8-dependent neurodevelopmental disorders. Using loss- and gain-of-function approaches in oligodendroglial cell lines and primary cell cultures, we show that Phf8 promotes the proliferation of rodent oligodendrocyte progenitor cells and impairs their differentiation to oligodendrocytes...
April 13, 2024: Glia
https://read.qxmd.com/read/38612902/agnostic-administration-of-targeted-anticancer-drugs-looking-for-a-balance-between-hype-and-caution
#9
REVIEW
Svetlana N Aleksakhina, Alexander O Ivantsov, Evgeny N Imyanitov
Many tumors have well-defined vulnerabilities, thus potentially allowing highly specific and effective treatment. There is a spectrum of actionable genetic alterations which are shared across various tumor types and, therefore, can be targeted by a given drug irrespective of tumor histology. Several agnostic drug-target matches have already been approved for clinical use, e.g., immune therapy for tumors with microsatellite instability (MSI) and/or high tumor mutation burden (TMB), NTRK1-3 and RET inhibitors for cancers carrying rearrangements in these kinases, and dabrafenib plus trametinib for BRAF V600E mutated malignancies...
April 7, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612726/targeting-group-3-medulloblastoma-by-the-anti-prune-1-and-anti-lsd1-kdm1a-epigenetic-molecules
#10
JOURNAL ARTICLE
Francesca Bibbò, Fatemeh Asadzadeh, Angelo Boccia, Carmen Sorice, Orazio Bianco, Carmen Daniela Saccà, Barbara Majello, Vittoria Donofrio, Delfina Bifano, Lucia De Martino, Lucia Quaglietta, Adriana Cristofano, Eugenio Maria Covelli, Giuseppe Cinalli, Veronica Ferrucci, Pasqualino De Antonellis, Massimo Zollo
Medulloblastoma (MB) is a highly malignant childhood brain tumor. Group 3 MB (Gr3 MB) is considered to have the most metastatic potential, and tailored therapies for Gr3 MB are currently lacking. Gr3 MB is driven by PRUNE-1 amplification or overexpression. In this paper, we found that PRUNE-1 was transcriptionally regulated by lysine demethylase LSD1/KDM1A. This study aimed to investigate the therapeutic potential of inhibiting both PRUNE-1 and LSD1/KDM1A with the selective inhibitors AA7.1 and SP-2577, respectively...
March 31, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38611088/early-stage-non-small-cell-lung-cancer-prevalence-of-actionable-alterations-in-a-monocentric-consecutive-cohort
#11
JOURNAL ARTICLE
Rossella Bruno, Anello Marcello Poma, Martina Panozzi, Alessandra Lenzini, Gianmarco Elia, Carmelina Cristina Zirafa, Vittorio Aprile, Marcello Carlo Ambrogi, Editta Baldini, Marco Lucchi, Franca Melfi, Antonio Chella, Andrea Sbrana, Greta Alì
Early-stage (ES) non-small cell lung cancer (NSCLC) is diagnosed in about 30% of cases. The preferred treatment is surgery, but a significant proportion of patients experience recurrence. Neoadjuvant and adjuvant chemotherapy has a limited clinical benefit. EGFR tyrosine kinase inhibitors and immunotherapy have recently opened new therapeutic scenarios. However, only a few data are available about the ES-NSCLC molecular landscape and the impact of oncogene addiction on therapy definition. Here, we determined the prevalence of the main lung cancer driver alterations in a monocentric consecutive cohort...
April 3, 2024: Cancers
https://read.qxmd.com/read/38611047/immunotherapy-for-thymomas-and-thymic-carcinomas-current-status-and-future-directions
#12
REVIEW
Arun Rajan, Alisa K Sivapiromrat, Meredith J McAdams
Thymic epithelial tumors are a histologically diverse group of cancers arising from the epithelial compartment of the thymus. These tumors are characterized by a low tumor mutation burden, a lack of actionable genomic changes, and, especially with thymomas, defects in immune tolerance. Surgery is the mainstay of the management of resectable disease, whereas advanced, unresectable tumors are treated with platinum-based chemotherapy. Disease recurrence can occur months to years after frontline treatment. Although several options are available for conventional treatment of recurrent thymic tumors, response rates are generally low, and treatment-related toxicity can affect quality of life...
March 30, 2024: Cancers
https://read.qxmd.com/read/38610927/intracranial-efficacy-of-atezolizumab-bevacizumab-carboplatin-and-paclitaxel-in-real-world-patients-with-non-small-cell-lung-cancer-and-egfr-or-alk-alterations
#13
JOURNAL ARTICLE
Marcus Rathbone, Conor O'Hagan, Helen Wong, Adeel Khan, Timothy Cook, Sarah Rose, Jonathan Heseltine, Carles Escriu
Contrary to Pemetrexed-containing chemo-immunotherapy studies, Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (ABCP) treatment has consistently shown clinical benefit in prospective studies in patients with lung cancer and actionable mutations, where intracranial metastases are common. Here, we aimed to describe the real-life population of patients fit to receive ABCP after targeted therapy and quantify its clinical effect in patients with brain metastases. Patients treated in Cheshire and Merseyside between 2019 and 2022 were identified...
March 22, 2024: Cancers
https://read.qxmd.com/read/38609130/education-from-dermatologists-the-simultaneously-development-of-16-keratinocytic-cancers-after-use-of-metformin-in-combination-with-losartan-hydrochlorothiazide-metoprolol-and-nifedipine-important-links-to-drug-related-photo-nitroso-carcinogenesis-and-oncopharmacogenesis
#14
JOURNAL ARTICLE
G Tchernev, D Dimova
Oncopharmacogenesis and Drug-Induced Skin cancer related Nitrosogenesis are newly introduced concepts in the medical literature that owe their genesis or presence to the carcinogens/ mutagens, also known as nitrosamines/NDSRIs, which are present in a heterogeneous class of drugs. The contribution to the origin of these 2 concepts is entirely due to 1) the functions and efficacy of FDA in terms of control and identification of these carcinogens, and 2) the establishment of clinicopathological correlations by the dermatologists, occurring during drug intake...
February 2024: Georgian Medical News
https://read.qxmd.com/read/38609110/-n-nitroso-propafenone-induced-advanced-nodular-melanoma-first-reported-case-in-the-world-literature-the-inextricable-links-between-the-photocarcinogenesis-drug-related-nitrosogenesis-and-pharmaco-oncogenesis
#15
JOURNAL ARTICLE
G Tchernev
Onco-pharmacogenesis or pharmaco-oncogenesis of skin cancer is a concept , which could also be considered as an "end product" of drug-mediated Nitrosogenesis or of the permissive regime for carcinogens to be (un)controlled released in drugs. Their controlled distribution remains until 2025 as a forced and non-alternative and there is no indication of any possibility to introduce a full elimination regime against the already mentioned carcinogenic availability. There are three main worrying facts that determine the need for these elimination regimes: 1) the clinicopathological correlations concerning the intake of a heterogeneous class of drugs and the subsequent development of relatively homogeneous tumours/ such as melanoma, 2) the recently proven mutagenic/ carcinogenic action of certain nitrosamines, but this time directly on human DNA, and 3) the fact that some of the nitrosamines are potent photocarcinogens that exert their genotoxic effects only after irradiation with UVA/ also recently proven/...
February 2024: Georgian Medical News
https://read.qxmd.com/read/38606464/target-mediated-fluoroquinolone-resistance-in-neisseria-gonorrhoeae-actions-of-ciprofloxacin-against-gyrase-and-topoisomerase-iv
#16
JOURNAL ARTICLE
Jessica A Collins, Alexandria A Oviatt, Pan F Chan, Neil Osheroff
Fluoroquinolones make up a critically important class of antibacterials administered worldwide to treat human infections. However, their clinical utility has been curtailed by target-mediated resistance, which is caused by mutations in the fluoroquinolone targets, gyrase and topoisomerase IV. An important pathogen that has been affected by this resistance is Neisseria gonorrhoeae , the causative agent of gonorrhea. Over 82 million new cases of this sexually transmitted infection were reported globally in 2020...
April 12, 2024: ACS Infectious Diseases
https://read.qxmd.com/read/38606235/two-cases-of-sporadic-amyotrophic-lateral-sclerosis-with-contrasting-clinical-phenotypes-genetic-insights
#17
Andrey Frolov, Miguel A Guzman, Ghazala Hayat, John R Martin
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease that affects individuals of diverse racial and ethnic backgrounds. There is currently no cure for ALS, and the number of efficient disease-modifying drugs for ALS is limited to a few, despite the large number of clinical trials conducted in recent years. The latter could be attributed to the significant heterogeneity of ALS clinical phenotypes even in their familial forms. To address this issue, we conducted postmortem genetic screening of two female patients with sporadic ALS (sALS) and contrasting clinical phenotypes...
March 2024: Curēus
https://read.qxmd.com/read/38605929/development-testing-and-validation-of-a-targeted-ngs-panel-for-the-detection-of-actionable-mutations-in-lung-cancer-nsclc-using-anchored-multiplex-pcr-technology-in-a-multicentric-setting
#18
JOURNAL ARTICLE
Jörg Kumbrink, Melanie-Christin Demes, Jan Jeroch, Andreas Bräuninger, Kristin Hartung, Uwe Gerstenmaier, Ralf Marienfeld, Axel Hillmer, Nadine Bohn, Christina Lehning, Ferdinand Ferch, Peter Wild, Stefan Gattenlöhner, Peter Möller, Frederick Klauschen, Andreas Jung
Lung cancer is a paradigm for a genetically driven tumor. A variety of drugs were developed targeting specific biomarkers requiring testing for tumor genetic alterations in relevant biomarkers. Different next-generation sequencing technologies are available for library generation: 1) anchored multiplex-, 2) amplicon based- and 3) hybrid capture-based-PCR. Anchored multiplex PCR-based sequencing was investigated for routine molecular testing within the national Network Genomic Medicine Lung Cancer (nNGM). Four centers applied the anchored multiplex ArcherDX-Variantplex nNGMv2 panel to re-analyze samples pre-tested during routine diagnostics...
2024: Pathology Oncology Research: POR
https://read.qxmd.com/read/38602795/telling-a-scientific-story-and-governing-the-population-the-kallikak-story-and-the-historical-mutations-of-the-eugenic-discourse
#19
JOURNAL ARTICLE
Thom Axelsson, Jonas Qvarsebo
In this article, we follow the trails of 20th-century psychologist Henry Herbert Goddard's influential study of the Kallikak family. Goddard's study is treated as a scientific story with two interlocking dimensions: One is the actual story of the Kallikak family, with literary elements such as setting, plot, and characters. The other dimension is the broader eugenic discourse, a powerful scientific narrative that calls for action in relation to society and the population. The purpose of the article is twofold...
April 11, 2024: History of Psychology
https://read.qxmd.com/read/38602058/exploring-the-tumor-genomic-landscape-of-aggressive-prostate-cancer-by-whole-genome-sequencing-of-tissue-or-liquid-biopsies
#20
JOURNAL ARTICLE
Simone Weiss, Philippe Lamy, Maria Rusan, Maibritt Nørgaard, Benedicte Parm Ulhøi, Michael Knudsen, Christine Gaasdal Kassentoft, Leila Farajzadeh, Jørgen Bjerggaard Jensen, Jakob Skou Pedersen, Michael Borre, Karina Dalsgaard Sørensen
Treatment resistance remains a major issue in aggressive prostate cancer (PC), and novel genomic biomarkers may guide better treatment selection. Circulating tumor DNA (ctDNA) can provide minimally invasive information about tumor genomes, but the genomic landscape of aggressive PC based on whole-genome sequencing (WGS) of ctDNA remains incompletely characterized. Thus, we here performed WGS of tumor tissue (n = 31) or plasma ctDNA (n = 10) from a total of 41 aggressive PC patients, including 11 hormone-naïve, 15 hormone-sensitive, and 15 castration-resistant patients...
April 11, 2024: International Journal of Cancer. Journal International du Cancer
keyword
keyword
163849
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.